Michael Chi Sells 17,303 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $9,319,952.14. This represents a 8.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Chi also recently made the following trade(s):

• On Monday, February 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.28, for a total value of $314,169.52.
• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.00, for a total value of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total transaction of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The stock was sold at an average price of $26.00, for a total transaction of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Trading Up 5.0 %

Shares of NYSE:HIMS opened at $41.87 on Thursday. The company has a 50-day moving average price of $35.89 and a 200-day moving average price of $26.36. The company has a market cap of $9.15 billion, a price-to-earnings ratio of 95.15 and a beta of 1.35. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after buying an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, State Street Corp raised its stake in Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after buying an additional 206,078 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on HIMS shares. Truist Financial upped their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Citigroup upped their price objective on shares of Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a research note on Tuesday. Finally, Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $34.47.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.